GE HealthCare's New CT Scanner Gains Regulatory Approval but Faces Mixed Market Reaction
On August 31, 2026, GE HealthCare (NASDAQ:GEHC) announced that its Photonova Spectra photon-counting CT scanner received CE Mark approval in Europe and had already secured FDA clearance in the U.S. and regulatory approval in Japan earlier in March 2026. The system uses Deep Silicon detector technology to capture detailed spectral data, enabling faster imaging with minimal motion artifacts. It also integrates NVIDIA's computing platform for efficient workflow processing. Despite these advancements, GE HealthCare reported mixed financial performance across its segments during the second quarter ended June 30, 2026. The company achieved record organic orders growth of 11.1% and a backlog of $23.9 billion but saw revenue decline in its Patient Care Solutions segment by 13.3%, which now operates at an EBIT loss. Management reaffirmed full-year guidance for modest top-line growth, citing ongoing inflationary pressures. The company's stock is trading at a forward P/E ratio of 14.71 and has seen slight hedge fund减持 from the previous quarter. While Photonova Spectra represents a technological leap in imaging solutions, investors remain cautious due to uneven performance across business units.
Topics: CT scanners healthcare medical technology NVIDIA partnership